Contact Congress about H.R. 5467: PAAT Act

Medicare drug plans would have to cover all qualifying drugs for autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027. For most of those drugs, plans could ask for prior approval only once a year.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

PAAT Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 5467: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects Medicare patients who take prescription drugs for autoimmune diseases, hemophilia, or Von Willebrand disease. It also affects doctors who handle drug approval requests and Medicare drug plans that decide which medicines they cover. Starting in 2027, those plans would have less room to exclude qualifying drugs or require repeat approval for them.

Why this matters: People who depend on these medicines can face delays when a plan does not cover a drug or asks for repeated approval. This bill could make coverage more consistent and reduce repeat paperwork for many patients and doctors. The tradeoff is that plans would have fewer tools to manage some drug costs and use. The bill does not settle what patients would pay out of pocket.

Key provisions in H.R. 5467

• Starting in 2027, Medicare Part D drug plans would have to cover every qualifying drug for autoimmune diseases, hemophilia, or Von Willebrand disease. The drug must be a covered Part D drug and must be used and prescribed for one of those conditions.
• All Part D plan sponsors would have to follow this coverage rule. They could not leave qualifying drugs off their covered drug lists if the drugs meet Part D rules.
• Plans could not ask the same enrollee for prior authorization more than once every 12 months for these drugs. Prior authorization means the plan requires approval before it pays for the medicine. This rule would start January 1, 2027.
• The once-a-year prior authorization limit would not apply to drugs usually used for 12 months or less. It also would not apply to opioids, benzodiazepines, barbiturates, or carisoprodol.
• The limit also would not apply to drugs with a required risk evaluation and mitigation strategy. That is a federal safety plan for drugs with serious risks under the Federal Food, Drug, and Cosmetic Act.

How Modern Action helps you take action on H.R. 5467

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 5467

What is H.R. 5467?

Medicare drug plans would have to cover all qualifying drugs for autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027. For most of those drugs, plans could ask for prior approval only once a year.

How do I support or oppose H.R. 5467?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 5467?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 5467 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.